Cargando…
Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study
The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received....
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592268/ https://www.ncbi.nlm.nih.gov/pubmed/36281169 http://dx.doi.org/10.1097/MD.0000000000031175 |
_version_ | 1784814886112460800 |
---|---|
author | Bonfill, Xavier Martinez-Zapata, María José Barrionuevo-Rosas, Leslie Vernooij, Robin WM Sánchez, María José Morales-Suárez-Varela, María De la Cruz, Javier Emparanza, José Ignacio Ferrer, Montserrat Pijoan, José Ignacio Palou, Joan Frances, Albert Madrid, Eva Coscia, Claudia Zamora, Javier |
author_facet | Bonfill, Xavier Martinez-Zapata, María José Barrionuevo-Rosas, Leslie Vernooij, Robin WM Sánchez, María José Morales-Suárez-Varela, María De la Cruz, Javier Emparanza, José Ignacio Ferrer, Montserrat Pijoan, José Ignacio Palou, Joan Frances, Albert Madrid, Eva Coscia, Claudia Zamora, Javier |
author_sort | Bonfill, Xavier |
collection | PubMed |
description | The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received. We conducted a multicenter, prospective, cohort study including primary bladder cancer patients during the first 12 months after diagnosis. The clinical outcomes were performance status (ECOG), adverse events and any cause of mortality. We stratified the analysis by factors that might influence the treatments received. We conducted univariate and multivariable logistic regression models to assess which patient and tumor characteristics were associated with receiving adjuvant treatment in the subgroup of noninvasive bladder cancer patients. In total, 314 patients were included (85% men; 53.8% >70 years) in 7 tertiary Spanish hospitals; 82.2% had a noninvasive urothelial bladder cancer (NMIBC). Patients received mostly surgery plus adjuvant therapy (67.7%). BCG (32.8% patients) was the most frequently administered adjuvant therapy, followed by intravesical chemotherapy (17.8% patients) and radiotherapy (10.8%). The variability of administered treatments among hospitals was low. Patients with NMIBC were more likely to receive adjuvant therapy if they had a higher educational level, some comorbidities and a high-grade tumor. The number of fully active patients (ECOG 0) significantly decreased during the first year of follow-up from 58% to 36 % (OR: 2.41, 95%CI 1.82–3.20); at 12-month follow-up 10.8% patients had died from any cause. In conclusion, most of the patients had a NMIBC. Surgery alone or plus adjuvant therapy were the commonest curative options of bladder cancer. BCG therapy was the adjuvant therapy most frequently administered. Higher educational level, presence of comorbidities and a high-grade tumor were associated with adjuvant therapy. Patient performance status was worsening over time. Almost 1 of 10 patients died during the first year of follow-up. |
format | Online Article Text |
id | pubmed-9592268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95922682022-10-25 Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study Bonfill, Xavier Martinez-Zapata, María José Barrionuevo-Rosas, Leslie Vernooij, Robin WM Sánchez, María José Morales-Suárez-Varela, María De la Cruz, Javier Emparanza, José Ignacio Ferrer, Montserrat Pijoan, José Ignacio Palou, Joan Frances, Albert Madrid, Eva Coscia, Claudia Zamora, Javier Medicine (Baltimore) 7300 The therapeutic approach of bladder cancer strongly determines its prognosis. We describe the treatments and outcomes for a Spanish cohort of patients with bladder cancer for the first 12 months after diagnosis and identify the factors that influenced the decision to undergo the treatment received. We conducted a multicenter, prospective, cohort study including primary bladder cancer patients during the first 12 months after diagnosis. The clinical outcomes were performance status (ECOG), adverse events and any cause of mortality. We stratified the analysis by factors that might influence the treatments received. We conducted univariate and multivariable logistic regression models to assess which patient and tumor characteristics were associated with receiving adjuvant treatment in the subgroup of noninvasive bladder cancer patients. In total, 314 patients were included (85% men; 53.8% >70 years) in 7 tertiary Spanish hospitals; 82.2% had a noninvasive urothelial bladder cancer (NMIBC). Patients received mostly surgery plus adjuvant therapy (67.7%). BCG (32.8% patients) was the most frequently administered adjuvant therapy, followed by intravesical chemotherapy (17.8% patients) and radiotherapy (10.8%). The variability of administered treatments among hospitals was low. Patients with NMIBC were more likely to receive adjuvant therapy if they had a higher educational level, some comorbidities and a high-grade tumor. The number of fully active patients (ECOG 0) significantly decreased during the first year of follow-up from 58% to 36 % (OR: 2.41, 95%CI 1.82–3.20); at 12-month follow-up 10.8% patients had died from any cause. In conclusion, most of the patients had a NMIBC. Surgery alone or plus adjuvant therapy were the commonest curative options of bladder cancer. BCG therapy was the adjuvant therapy most frequently administered. Higher educational level, presence of comorbidities and a high-grade tumor were associated with adjuvant therapy. Patient performance status was worsening over time. Almost 1 of 10 patients died during the first year of follow-up. Lippincott Williams & Wilkins 2022-10-21 /pmc/articles/PMC9592268/ /pubmed/36281169 http://dx.doi.org/10.1097/MD.0000000000031175 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 7300 Bonfill, Xavier Martinez-Zapata, María José Barrionuevo-Rosas, Leslie Vernooij, Robin WM Sánchez, María José Morales-Suárez-Varela, María De la Cruz, Javier Emparanza, José Ignacio Ferrer, Montserrat Pijoan, José Ignacio Palou, Joan Frances, Albert Madrid, Eva Coscia, Claudia Zamora, Javier Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study |
title | Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study |
title_full | Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study |
title_fullStr | Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study |
title_full_unstemmed | Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study |
title_short | Follow-up care of 12 months of patients with bladder cancer in Spain: A multicenter prospective cohort study |
title_sort | follow-up care of 12 months of patients with bladder cancer in spain: a multicenter prospective cohort study |
topic | 7300 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592268/ https://www.ncbi.nlm.nih.gov/pubmed/36281169 http://dx.doi.org/10.1097/MD.0000000000031175 |
work_keys_str_mv | AT bonfillxavier followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT martinezzapatamariajose followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT barrionuevorosasleslie followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT vernooijrobinwm followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT sanchezmariajose followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT moralessuarezvarelamaria followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT delacruzjavier followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT emparanzajoseignacio followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT ferrermontserrat followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT pijoanjoseignacio followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT paloujoan followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT francesalbert followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT madrideva followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT cosciaclaudia followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy AT zamorajavier followupcareof12monthsofpatientswithbladdercancerinspainamulticenterprospectivecohortstudy |